Special Issue "The Role of MicroRNA in Cancer"
Deadline for manuscript submissions: closed (20 October 2021).
Interests: general and molecular pathology, cancer molecular pathogenesis, microRNA, cell cycle, apoptosis, inflammation
Interests: cancer molecular pathogenesis; inflammation; NF-kB signaling; apoptosis; preclinical models; new therapeutic targets identification; epatocarcinogenesis; microRNA
Interests: oncogenes, tumor suppressor genes, cancer molecular diagnostics, personalized medicine, epatocarcinogenesis, microRNA, profiling, bioinformatics
During the last decade, three classes of non-coding RNAs gained great attention. Among them, microRNAs, short (18-22 nucleotide in length) endogenous non-coding RNAs, play a role in regulating the expression of target genes at the post-transcriptional level. MicroRNAs are involved in the control of fundamental cell processes, such as growth, proliferation, differentiation, cell cycle, and programmed death. Dysregulation or aberrant microRNAs’ expression levels and different profiles are described in important pathological conditions, such as cardiovascular, neurological diseases, and cancer. It is known that tumour initiation, progression, and metastasis dissemination are correlated to significant changes in gene expression; for this reason, in the last decade, a large and increasing number of studies has been focused on examining in depth the role of microRNAs in tumorigenesis. Depending on the function of target genes, microRNAs can show tumour promoting (oncomiR) or suppressive (tumor suppressor miRs) properties in cancers, by regulating the expression of entire groups of genes implicated in oncogenesis and metastasis. MicroRNAs are considered as early diagnostic, prognostic, and predictive biomarkers as well. In addition, dysregulated miRNAs produced in the tumour microenvironment can be released into the bloodstream because of passive or active mechanisms. Due to their structure and nature, circulating microRNAs are resistant to endogenous RNase and very stable even in difficult conditions; for this reason, they are considered as suitable and promising non-invasive biomarkers. Novel therapeutic anti-cancer strategies are directed to target dysregulated/aberrantly expressed key microRNAs to re-establish normal physiological conditions, by inhibiting or restoring their normal expression levels. To this aim, the identification of improved and effective delivery systems is of great relevance. Importantly, such new generation- targeted therapies might be considered in combination regimens or as secondary treatment in cancers which are unresponsive to conventional therapeutic schemes.
In this Special Issue, we are interested in recent advances and opinions on the role of non-coding RNAs in oncogenesis. Research papers and reviews will focus on, but are not limited to, the role of microRNAs in tumorigenesis; microRNAs as biomarkers in cancer; therapeutic use of microRNAs in cancer, strategies and delivery systems to restore microRNA expression levels; microRNA preclinical models and bioinformatics approaches for miRNAs/target genes analysis.Prof. Edoardo Alesse
Prof. Francesca Zazzeroni
Dr. Alessandra Tessitore
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- non-coding RNAs
- preclinical models
- microRNA-based therapy